期刊文献+

荧光原位杂交技术在尿路上皮癌筛查中价值 被引量:5

Value of fluorescence in situ hybridization to the screening of urothelial carcinoma
原文传递
导出
摘要 目的评估尿脱落细胞学及荧光原位杂交技术(fluorescence in situ hybridization,FISH)检测在筛查尿路上皮癌中的特异性及敏感性,分析各畸变染色体与尿路上皮癌的关系。方法对156例血尿患者(血尿组)和20例体检健康者(对照组)分别行普通细胞学和FISH检测。以手术或组织活检病理检测结果验证FISH检测技术及细胞学检测结果的准确性,比较2种检测技术在尿路上皮癌筛查中的敏感性和特异性,分析3、7、17号染色体及p16位点在尿路上皮癌中的畸变概率。结果血尿组FISH检测和尿脱落细胞学检测诊断尿路上皮癌的敏感性分别为91.6%和40.2%,二者比较差异有统计学意义(χ2=33.802,P=0.000);特异性分别为95.9%和97.7%,二者比较差异无统计学意义(P>0.05);3、7、17号染色体及p16位点畸变的概率分别为63.0%、64.1%、67.4%、75.0%。结论 FISH检测可明显提高尿路上皮癌术前诊断准确性,可了解尿路上皮癌患者尿脱落细胞染色体畸变情况。 Objective To assess the specificity and sensitivity of fluorescence in situ hybridization (FISH) technique to the diagnosis of urothelial carcinoma, and explore the relationship of chromosome aberration with urothelial carcinoma. Methods FISH and cytology technique were used in 156 patients with haematuria and 20 normal controls. The accuracies of them were tested by operation or pathology results. The sensitivity and specificity of FISH were evaluated and compared with cytology technique. The aberration rates of chromosome CSP3, CSP7, CSP17 and GLPpl6 were analyzed. Results The sensitivities of FISH and cytology technique for the urothelial carcinoma were 91. 6% and 40. 2% in haematuria patients, which showed a significant difference (χ2= 33. 802, P= 0. 000). There was no significant difference in the specificities between FISH (95. 9%) and cytology technique (97. 7%)(P〈 0. 05). The aberration rates of chromosome CSP3, CSP7, CSP17 and GLPp16 were 63.0%, 64.1%, 67.4% and 75.0%. Conclusion FISH technique improves the diagnostic accuracy of urothelial carcinoma before operation, and shows the chromosome aberration status in urinary exfoliated cells in the urothelial carcinoma patients.
出处 《中华实用诊断与治疗杂志》 2013年第10期951-953,共3页 Journal of Chinese Practical Diagnosis and Therapy
基金 国家自然科学基金资助项目(No.81172874)
关键词 尿路上皮癌 荧光原位杂交技术 普通细胞学检测技术 Urothelial carcinoma fluorescence in situ hybridization cytology
  • 相关文献

参考文献11

  • 1Ratliff T L. Urine markers for bladder cancer surveillance: a systematic review[J]. J Urol, 2005,174(5):2065-2066.
  • 2Jones J S. DNA based molecular cytology for bladder cancer surveillance[J]. Urology, 2006,67 (31): 35-47.
  • 3Reid-Nicholson M D, Ramalingam P, Adeagbo B, et al. The use of Urovysion fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder[J]. Mod Pathol,2009,22(1) :119-127.
  • 4Lotan Y, Bensalah K, Ruddell T, et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder[J]. J Urol, 2008,179(6) :2164- 2169.
  • 5Marin Aguilera M, Mengual L, Ribal M J, et al. Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer [J]. Cancer Genet Cytogenet,2007,173(2) :131- 135.
  • 6Kwak K W, Kim S H, Lee H M, et al. The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice[J]. J Korean Med Sci,2009,24(6) :1139-1144.
  • 7单正飞,郑少斌,吴芃,谭万龙,左翼,周海宽,齐桓,张鹏,彭红梅.荧光原位杂交技术在膀胱癌诊断中的应用价值[J].南方医科大学学报,2010,30(7):1597-1599. 被引量:7
  • 8Varella-Garcia M, Akduman B, Supaweravog P, et al. The urovysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer[J]. Urol Oncol, 2004,22(1) :16 -19.
  • 9Sarosdy M F, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi target fluorescence in situ hybridization assay for detection of bladder cancer[J]. J Urol,2002,168(3) 1950-1954.
  • 10Yoder B J, Skaeel M, Hedgepeth R, et al. Reflex urovysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology[J]. Am J Clin Pathol, 2007,127 (2) : 295 -301.

二级参考文献12

  • 1Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations [ J ]. Urology, 1995, 45(3): 387-396.
  • 2Sandberg AA, Berger CS. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer [J]. J Urol, 1994, 151(3): 545-60.
  • 3Sokolova IA, Hailing KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection ofurothelial carcinoma in urine [J]. J Mol Diagn, 2000, 2(3): 116-23.
  • 4Friedrich MG, Toma MI, Hellstern A, et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer [J]. BJU Int, 2003, 92 (9): 911-4.
  • 5BubendorfL, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings[J]. Am J Clin Pathol, 2001, 116(1): 79-86.
  • 6Zhang J, Zheng S, Gao Y, et al. A partial allelotyping of urothelial carcinoma of bladder in the Chinese [J]. Carcinogenesis, 2004, 25 (3): 343-7.
  • 7Lotan Y, Bensalah K, Ruddell T, et al. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder[J]. J Urol, 2008, 179(6): 2164-9.
  • 8Kwak C, Ku JH, Park JY, ct al. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer[J]. J Urol, 2004, 171(1): 149-52.
  • 9Hailing KC, Kipp BR. Bladder cancer detection using FISH (UroVysion assay)[J]. Adv Anat Pathol, 2008, 15(5): 279-86.
  • 10Skacel M, Fahmy M, Brainard JA, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology[J]. J Urol, 2003, 169(6): 2101-5.

共引文献6

同被引文献56

  • 1麦海星,陈彪,陈立军,曲楠,赵立,王亚林,黄晨,李学超.荧光原位杂交技术联合输尿软镜筛查早期上尿路肿瘤[J].微创泌尿外科杂志,2013,2(2):123-125. 被引量:3
  • 2张栋,孙鹏.膀胱肿瘤标记物及检测方法的研究进展[J].泌尿外科杂志(电子版),2012,4(3):33-35. 被引量:2
  • 3陈松,徐阿祥,孙圣坤,杨淑霞,张旭.荧光原位杂交技术在上尿路的尿路上皮癌诊断中的临床意义[J].微创泌尿外科杂志,2014,3(3):181-185. 被引量:5
  • 4Reynolds JP, Voss JS, Kipp BR, et al. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples[J].Cancer Cytopathol, 2014,122(6) :459-467.
  • 5Abat D, Demirhan O, Inandiklioglu N, et al. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer[J]. Oncol Lett, 2014,8 (1) : 25-32.
  • 6Dimashkieh H, Wolff DJ, Smith TM, et al. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation [J]. Cancer Cytopathol,2013,121(10):591-597.
  • 7Li HX, Wang MR, Zhao H, et al. Comparison of fluorescence in situ hybridization, NMP22 bladder chek, and urinary liquid- based cytology in the detection of bladder urothelial carcinoma [J]. Diagn Cytopathol,2013,41(10) :852-857.
  • 8S~inehez-Carbayo M. Hypermethylation in bladder cancer: biological pathways and translational applications [J]. Turnout Biol,2012,33(2) :347-361.
  • 9Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16[J~. Int J Cancer, 2012, 130(8) :1715-1725.
  • 10Roupret M,Colin P. Urothelial carcinomas of the upper u- rinary tract arenow recognised as atrue and distinct entity from bladder cancer and belong fully to the broad spec- trum of onco-urologic neoplasms[J]. World J Urol, 2013, 31(1) :1-3.

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部